-
公开(公告)号：US11129806B2
公开(公告)日：2021-09-28
申请号：US15647016
申请日：2017-07-11
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US11007166B2
公开(公告)日：2021-05-18
申请号：US16936398
申请日：2020-07-22
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US11007167B2
公开(公告)日：2021-05-18
申请号：US17071740
申请日：2020-10-15
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
IPC: A61K31/225 , A61K31/40 , A61K9/00 , A61K9/28 , A61K9/48 , G01N33/49 , G09B19/00 , A61K47/54 , A61P25/00
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US10959972B2
公开(公告)日：2021-03-30
申请号：US16173723
申请日：2018-10-29
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
IPC: A61K31/225 , A61K31/40 , A61K9/00 , A61K9/28 , A61K9/48 , G01N33/49 , G09B19/00 , A61K47/54 , A61P25/00
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US20210023040A1
公开(公告)日：2021-01-28
申请号：US17071740
申请日：2020-10-15
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
Patent Agency Ranking
公开(公告)号：US20200345679A1
公开(公告)日：2020-11-05
申请号：US16936398
申请日：2020-07-22
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US20210315854A1
公开(公告)日：2021-10-14
申请号：US17321788
申请日：2021-05-17
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US20190125710A1
公开(公告)日：2019-05-02
申请号：US16173723
申请日：2018-10-29
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US20190008817A1
公开(公告)日：2019-01-10
申请号：US16043641
申请日：2018-07-24
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
公开(公告)号：US20170368013A1
公开(公告)日：2017-12-28
申请号：US15647016
申请日：2017-07-11
Applicant: Biogen MA Inc.
Inventor： Mark Novas , Rui (Ray) Zhang
IPC: A61K31/225 , A61K47/54 , A61K9/00 , A61K9/48
CPC classification number: A61K31/225 , A61K9/0053 , A61K9/28 , A61K9/4808 , A61K9/4825 , A61K9/485 , A61K9/4858 , A61K9/4866 , A61K47/542 , A61K47/545 , G01N33/492 , G09B19/00 , Y02A50/467
Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
-
-
-
-
-
-
-
-
-
Search Results
13
records
(took 0.024 seconds)
